Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial

CONCLUSIONS: These findings indicate that treatment with cemdisiran resulted in a reduction of proteinuria at week 32 and was well tolerated.PMID:38214599 | DOI:10.2215/CJN.0000000000000384

Source: Clinical Journal of the American Society of Nephrology : CJASN - January 12, 2024 Category: Urology & Nephrology Authors: Jonathan Barratt Adrian Liew See Cheng Yeo Anders Fernstr öm Sean J Barbour C John Sperati Russell Villanueva Ming-Ju Wu Dazhe Wang Anna Borodovsky Prajakta Badri Elena Yureneva Ishir Bhan Daniel Cattran Cemdisiran Phase 2 Study Investigators and Collabo Source Type: research